RJA
HQL

Raymond James & Associates’s abrdn Life Sciences Investors HQL Stock Holding History

Raymond James & Associates’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$666K Buy
44,147
+4,812
+12% +$72.8K ﹤0.01% 2936
2024
Q2 		$557K Buy
39,335
+9,580
+32% +$130K ﹤0.01% 3009
2024
Q1 		$406K Buy
29,755
+3,433
+13% +$47.5K ﹤0.01% 3197
2023
Q4 		$354K Sell
26,322
-1,449
-5% -$17.8K ﹤0.01% 3176
2023
Q3 		$346K Sell
27,771
-136,694
-83% -$1.8M ﹤0.01% 3112
2023
Q2 		$2.23M Sell
164,465
-145,739
-47% -$2.01M ﹤0.01% 1990
2023
Q1 		$4.32M Buy
310,204
+54,721
+21% +$782K ﹤0.01% 1559
2022
Q4 		$3.63M Buy
255,483
+85,818
+51% +$1.24M ﹤0.01% 1637
2022
Q3 		$2.32M Buy
169,665
+157,719
+1,320% +$2.36M ﹤0.01% 1881
2022
Q2 		$170K Sell
11,946
-12,261
-51% -$185K ﹤0.01% 3561
2022
Q1 		$400K Sell
24,207
-57,169
-70% -$984K ﹤0.01% 3211
2021
Q4 		$1.56M Buy
81,376
+17,292
+27% +$348K ﹤0.01% 2335
2021
Q3 		$1.33M Sell
64,084
-29
-0% -$621 ﹤0.01% 2388
2021
Q2 		$1.38M Buy
64,113
+2,623
+4% +$53K ﹤0.01% 2376
2021
Q1 		$1.21M Buy
61,490
+30,412
+98% +$627K ﹤0.01% 2371
2020
Q4 		$614K Sell
31,078
-21,190
-41% -$392K ﹤0.01% 2679
2020
Q3 		$919K Sell
52,268
-1,554
-3% -$27.8K ﹤0.01% 2219
2020
Q2 		$967K Sell
53,822
-13,000
-19% -$223K ﹤0.01% 2186
2020
Q1 		$1M Sell
66,822
-21,275
-24% -$348K ﹤0.01% 1980
2019
Q4 		$1.54M Sell
88,097
-78,806
-47% -$1.29M ﹤0.01% 1997
2019
Q3 		$2.52M Sell
166,903
-49,674
-23% -$796K ﹤0.01% 1633
2019
Q2 		$3.65M Sell
216,577
-61,525
-22% -$1.01M 0.01% 1421
2019
Q1 		$4.76M Sell
278,102
-18,205
-6% -$314K 0.01% 1219
2018
Q4 		$4.48M Sell
296,307
-15,668
-5% -$276K 0.01% 1163
2018
Q3 		$6.37M Buy
311,975
+8,581
+3% +$171K 0.01% 1075
2018
Q2 		$5.7M Buy
303,394
+29,296
+11% +$551K 0.01% 1120
2018
Q1 		$5.27M Buy
274,098
+27,080
+11% +$542K 0.01% 1131
2017
Q4 		$4.85M Buy
247,018
+140,994
+133% +$2.82M 0.01% 1143
2017
Q3 		$2.28M Sell
106,024
-3,288
-3% -$69.9K ﹤0.01% 1564
2017
Q2 		$2.28M Buy
109,312
+14,039
+15% +$284K ﹤0.01% 1485
2017
Q1 		$1.85M Buy
95,273
+18,735
+24% +$347K ﹤0.01% 1574
2016
Q4 		$1.3M Buy
76,538
+57,671
+306% +$1.01M ﹤0.01% 1780
2016
Q3 		$353K Buy
18,867
+3,837
+26% +$72.3K ﹤0.01% 2511
2016
Q2 		$258K Buy
+15,030
New +$277K ﹤0.01% 2500
2016
Q1 		– Sell
-10,451
Closed -$247K – 2943
2015
Q4 		$247K Sell
10,451
-11,386
-52% -$282K ﹤0.01% 2269
2015
Q3 		$492K Sell
21,837
-4,193
-16% -$117K ﹤0.01% 1932
2015
Q2 		$734K Sell
26,030
-2,911
-10% -$80.7K ﹤0.01% 1877
2015
Q1 		$798K Buy
+28,941
New +$789K ﹤0.01% 1795
2014
Q3 		– Sell
-38,353
Closed -$796K – 2192
2014
Q2 		$796K Buy
38,353
+17,364
+83% +$364K ﹤0.01% 1625
2014
Q1 		$457K Buy
20,989
+10,900
+108% +$243K ﹤0.01% 1822
2013
Q4 		$206K Buy
+10,089
New +$196K ﹤0.01% 1950

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
AIA
Absolute Investment Advisers Rosemary Beach, Florida $852M AUM 0.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Raymond James & Associates's HQL Position: Q3 2024 in Review

Raymond James & Associates increased its abrdn Life Sciences Investors (HQL) stake by 12% in Q3 2024, buying an estimated $72.8K and bringing the position to 44,147 shares worth $666K. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Raymond James & Associates first reported a position in HQL in Q4 2013 and has held it in 41 quarters since. The position peaked at $6.37M in Q3 2018. 74 funds tracked by Wall St. Rank hold HQL as of Q3 2024.

  • Raymond James & Associates held 44,147 shares of abrdn Life Sciences Investors worth $666K as of Q3 2024.
  • Raymond James & Associates bought 4,812 abrdn Life Sciences Investors shares in Q3 2024, an estimated $72.8K.
  • abrdn Life Sciences Investors made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2936 holding.
  • Raymond James & Associates first reported a position in abrdn Life Sciences Investors in Q4 2013 and has held it in 41 quarters since.
  • Raymond James & Associates's abrdn Life Sciences Investors position peaked at $6.37M in Q3 2018.
  • 74 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.